Last reviewed · How we verify

NCT04831970: POPART

POst-Prostatectomy Ablative Radiation Therapy

Recruiting now Last updated 25 October 2022
What this trial tests

trial in Radiation Toxicity in 30 participants. Currently enrolling.

Timeline
15 April 2021
Primary endpoint
30 April 2026
31 December 2026

Quick facts

Lead sponsorUniversity of Milano Bicocca
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment30
Start date15 April 2021
Primary completion30 April 2026
Estimated completion31 December 2026
Sites2 locations across Italy

Conditions studied

Sponsor

University of Milano Bicocca

Who can join

Adults 18 to 90, male only, with Radiation Toxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of hypofractionated radiotherapy for prostate cancer has matured to a point that in current guidelines extremely hypofractionated image-guided IMRT regimens (6 Gy per fraction or greater) can be considered an alternative to conventionally fractionated regimens at clinics with appropriate technology, physics and clinical expertise. The delivery of fewer and larger fractions with hypofractionation compared to conventional radiotherapy might effectively improve the therapeutic ratio while maintaining isoeffective tumour doses, thus, shortening overall treatment time. In the present study, patients will undergo postoperative image-guided SBRT by means of volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with state-of-the-art treatment-planning and quality assurance procedures. Normal tissue sparing and delivery accuracy are accomplished by the use of devices that ensure stability and beam location reproducibility. The primary endpoint is to evaluate the cumulative incidence of treatment related toxicities and adverse events in the acute (\< 90 days from the end of treatment) and late (\> 90 days) setting.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial.
    Lucchini R, Franzese C, Vukcaj S, Purrello G, et al · · 2022 · cited 8× · PMID 36547147 · DOI 10.3390/curroncol29120733
  2. Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.
    Nikitas J, Ballas LK, Romero T, Lynch C, et al · · 2025 · cited 6× · PMID 40372727 · DOI 10.1001/jamaoncol.2025.1059
  3. Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study.
    Ferrario F, Franzese C, Faccenda V, Vukcaj S, et al · · 2024 · cited 5× · PMID 38111610 · DOI 10.1016/j.ctro.2023.100704
  4. Image-Guided Stereotactic Body Radiotherapy on Detectable Prostate Bed Recurrence after Prostatectomy in RT-Naïve Patients.
    Santamaria R, Zaffaroni M, Vincini MG, Colombi L, et al · · 2024 · cited 2× · PMID 39063623 · DOI 10.3390/life14070870

Verify or expand the search:

Other recruiting trials for Radiation Toxicity

Currently open trials in the same condition.

Other University of Milano Bicocca trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing